0001104659-22-077083.txt : 20220705 0001104659-22-077083.hdr.sgml : 20220705 20220705082844 ACCESSION NUMBER: 0001104659-22-077083 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220628 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220705 DATE AS OF CHANGE: 20220705 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Eloxx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001035354 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 841368850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31326 FILM NUMBER: 221063256 BUSINESS ADDRESS: STREET 1: 480 ARSENAL WAY STREET 2: SUITE 130 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 781-577-5300 MAIL ADDRESS: STREET 1: 480 ARSENAL WAY STREET 2: SUITE 130 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: Sevion Therapeutics, Inc. DATE OF NAME CHANGE: 20140930 FORMER COMPANY: FORMER CONFORMED NAME: SENESCO TECHNOLOGIES INC DATE OF NAME CHANGE: 19991006 FORMER COMPANY: FORMER CONFORMED NAME: NAVA LEISURE USA INC DATE OF NAME CHANGE: 19970310 8-K 1 tm2219962d1_8k.htm FORM 8-K
0001035354 false 0001035354 2022-06-28 2022-06-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

  

FORM 8-K

 

 

  

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 28, 2022

 

 

 

Eloxx Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

  

Delaware   001-31326   84-1368850

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

480 Arsenal Way, Suite 130, Watertown, MA

   02451
(Address of principal executive offices)   (Zip Code)

 

(Registrant’s telephone number, including area code): (781) 577-5300

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value per share ELOX The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Director Resignations

 

On June 28, 2022, each of Ran Nussbaum and Jasbir Seehra notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of their respective resignations from the Board and the respective committees of the Board on which they serve. On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve. Each of the foregoing resignations is effective as of July 1, 2022 (the “Effective Time”) and did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

Concurrently with the foregoing resignations and as of the Effective Time, the Board decreased its size from a total of nine directors to five directors authorized to serve on the Board and appointed Alan Walts as Chairperson of the Compensation Committee of the Board and Tomer Kariv as Chairperson of the Nominating and Corporate Governance Committee of the Board.

 

Director Appointment

 

On June 30, 2022, the Board appointed Lindsay Androski to serve as a director on the Company’s Board to fill the remaining vacancy and as a member of the Board’s Audit Committee and Compensation Committee, in each case, effective as of the Effective Time. Ms. Androski will serve for a term expiring at the Company’s annual meeting of stockholders to be held in 2023 and until her respective successor is duly elected and qualified or her earlier death, disqualification, resignation or removal.

 

Ms. Androski is eligible to participate in the Company’s non-employee director compensation program, which provides for: (i) an annual cash retainer of $40,000 for serving on the Board; (ii) an initial equity-based award of an option to purchase 40,000 shares of the Company’s common stock on initial appointment to the Board; and (iii) an annual equity-based award of an option to purchase 20,000 shares of the Company’s common stock upon reelection to the Board at the Company’s annual meeting of stockholders, with each such equity award to have an exercise price per share of common stock equal to the Fair Market Value (as defined in the Company’s 2018 Equity Incentive Plan) as of the grant date and to vest as to 50% of the underlying shares on the first annual anniversary of the grant date and the remainder in 12 equal monthly installments thereafter, subject to the director’s continued service on the Board through such vesting date. Ms. Androski is also eligible to receive to an annual cash retainer of $7,500 for serving as a member of the Audit Committee of the Board and $7,500 for serving as a member of the Compensation Committee of the Board.

 

Ms. Androski is expected to enter into the Company’s standard form indemnification agreement in the form filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K (File No. 001-31326), filed with the Securities and Exchange Commission on December 22, 2017.

 

Item 7.01Regulation FD Disclosure.

 

On July 5, 2022, the Company issued a press release announcing the foregoing Board changes. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information in this Item 7.01 (including Exhibit 99.1) of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

  

Item 9.01Financial Statements and Exhibits.

 

(d)   Exhibits.

 

Exhibit No.   Description
     
99.1   Press Release of Eloxx Pharmaceuticals, Inc., dated July 5, 2022.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

Date: July 5, 2022 ELOXX PHARMACEUTICALS, INC.
     

 By:

/s/ Sumit Aggarwal 

  Name: Sumit Aggarwal
  Title: President and Chief Executive Officer

 

 

 

 EX-101.SCH 2 elox-20220628.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 elox-20220628_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 elox-20220628_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-99.1 5 tm2219962d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Eloxx Pharmaceuticals Announces Changes to Board of Directors

 

Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures

 

Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra step down from the Eloxx board

 

 

WATERTOWN, MA – July 5, 2022 – Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board’s Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board. Following these changes, Eloxx’s board is now comprised of five directors.

 

“Lindsay is a veteran biotech executive with significant experience growing companies during her long tenure with the founding team of Roivant Sciences and now as President and CEO of Roivant Social Ventures,” said Sumit Aggarwal, President and CEO of Eloxx Pharmaceuticals. “Her current focus on early stage biotech companies improving health access will be extremely valuable to Eloxx as we continue to build a leadership position in genetic therapy.”

 

“I am passionate about companies like Eloxx that are focused on addressing unmet needs for underserved patient populations. I am excited to join the board of Eloxx and to contribute to the company’s work in developing therapies for rare diseases,” said Ms. Androski.

 

“In addition, I would like to express my sincerest gratitude to Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehr, for their dedication, impactful contributions, and valuable insights as they helped Eloxx navigate through challenging times,” said Sumit Aggarwal. “This smaller board, nimble and focused by design, supports the transformation we started in April 2021 with our acquisition of Zikani.”

 

Ms. Androski, JD, MBA is founder, President and CEO of Roivant Social Ventures, a social impact organization that makes early stage investments and incubates biotech companies focused on improving healthcare access and outcomes for underserved groups. A noted expert in the creation, launch and scaling of biotech companies, Ms. Androski joined the founding team at Roivant Sciences to build and lead the group responsible for the in-license or acquisition of more than 30 pharmaceutical drug candidates, where she was also instrumental in the launch of 16 biotech companies and participated in three IPOs and several private financings. To date, these efforts have led to five approved drugs now available to patients: Orgovyx (prostate cancer), Myfembree (heavy menstrual bleeding / uterine fibroids), Gemtesa (overactive bladder), Rethymic (pediatric congenital athymia), and VTAMA (plaque psoriasis). Prior to joining Roivant Sciences, Ms. Androski spent a decade as a trial lawyer, including four years as an Assistant U.S. Attorney in the newly-launched Cybercrime unit of the Eastern District of Virginia, where she led investigations and prosecutions of high-profile cybercrime and national security cases. .. Ms. Androski holds two BS degrees from the Massachusetts Institute of Technology, JD and MBA degrees from The University of Chicago, is a registered Patent Lawyer and a CFA charterholder (under her former name of Lindsay Androski Kelly). Ms. Androski also serves as a Trustee of the Massachusetts Institute of Technology, and sits on the Visiting Committees for the Department of Biology, the Department of Humanities, and Sponsored Research.

 

 

 

 

 

About Eloxx Pharmaceuticals

 

Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZMTM chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02 for the treatment of CF patients with nonsense mutations. In addition, ELX-02 has also been granted Orphan Drug Designation for the treatment of CF patients with nonsense mutations by the FDA and orphan medicinal product designation by the European Commission. ELX-02 is in clinical development, focusing on cystic fibrosis (US Trial NCT04135495, EU/IL Trial NCT04126473). Eloxx also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.

 

For more information, please visit www.eloxxpharma.com.

 

Contact

 

Investors

John Woolford

john.woolford@westwicke.com

443.213.0506

 

Media

Laureen Cassidy

laureen@outcomescg.com

 

 

 GRAPHIC 6 tm2219962d1_ex99-1img001.jpg GRAPHIC begin 644 tm2219962d1_ex99-1img001.jpg M_]C_X 02D9)1@ ! 0$ R #( #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" !Z )D# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H MHHH **** "BBB@ HHI#G''7WH 6F2 %"#TX_F,?K2[L9W$9]!FF2[BI R =I MR!R/F!_IZ=#CK45)JG'FE)Q5[.:7,H7^V^T8[MV:5M40WS0E:#E[K]R7N\^G MPZ_S;'AW[2OQ9U;X%? +XQ?&30?!U_\ $#6/AE\.?%WC?3?!6ER/%?\ B6Z\ M-:)=ZK#I$$T<%U) +MK41S3QVUS+##YDD<$SJL;?B#_P1C_X+%?'#_@HI\7O MBG\*_B[\)?ASX>7P9X'G\>:7XW^%D7B:TT"U6'Q!I&A+X1UB#Q%XF\8M?:G> MQZV;[3]8AU/0'GCT+5XY/#$(=);?^AV^19X9+=L,7C8*,,07_@#JJR;EWA=R MF-XV4,LBO&76OY=/@A_P5&^('@?_ (*UZ[^P%X%_8[^#/PX^#M_\;?%/PZN) M? 7@2_\ !_Q5UNWTB+78;#XVZSK&F:Q9>%-?\,O:V%QKMS#=>%)-0BT;Q'#G M41=Z?<7"IYEDV=X6GE.&S''8;!XG,_[0J8J-!X/#86FZ]7$4XS]VK5 MC"G*4**CSS Q.*PF#>$PN$GB:5>I6K0A[ M+$SA4@J%&;DHU*\N:-.*T4V[*[LE?1=7V74!:9(2$)'JHZ9QE@,D9&0N44ML5=S.1R8T 89=ON)S]\C@]*^;OVC/V@=,^!W@Z/4I(K/5/$NK2B'P[ MH#7)M7N9$/VAM1N66=9(]-L$CVW2D*;JX>.V1E65@.7'8W#Y?@JV.Q,^2C1H MU*TE:]1QIP[F+LBF*.,E5;>2%#,OQ;X MG_X*)?#73S-'X6\*>+/$;6\FQKRZCLO#^FS@.%+VUSMAW4E2J3TIU7A&^:NH2:E[!3BZEN3F5[GS.+SF MO6O2PG[OVB<(U)*S@Y:*5G?X6[I?*[W/U27_ (*0:'.2MS\*-2\LN@D(\7VC ML8@X,A2,:&ADF5-QBB$D?FR!(RZ;BX_.:?\ X+AW]M_P43\)_LW7/[,L.G?# M_7;S1_"WB/XH7>KRGQ^MOK'ANQUVX\6:=I6GZ=-I\W@GP^#J*:U'?WT-W'!# M)<6MV);=+27A[BY@LVA2ZGM4:?4%L;4WNI0Z3;W[&>;>+::_NE5W@M7L7;DB M2X=D EC5/A?]EGQ7^U_XD^*GQ.C_:$\ Z9H'A31]UOX*UA?#>FZ+=M*-9M; M:VT:QU6+4+R^UCPUY#M>7$%X]U=O]G5_MZ6JRPO]5P/Q9G2ROB_B+.Z>'QF# MR[*L7@:6,KYA#AZ5?,*F&G]7EE^4UHU:F;TZ-90E5I4:T$W%0DF[6^5S7.L; M6Q.6X.6+G6EA\;AIR3H63Y:L&[3UNVDU=6]=F?VK^$?%>B>,-+L]<\.ZK8ZY MI6I&YN+/5-.G2:RECCD,421R)DM,T"HX@8!T197D9OD)[,#.T]P,_F.:_%K_ M ()\^,O$5C\5[_P9:374_AS7?#>HZQJ%@[F2SLKK2KG[/IVMQQ)LM[&?4$,E MBPM(H(9XGCS#N4N?VA5FRH)4@CG&C\+U71 M/5KL?I>%JRK8:C.4)W?+KRMI--.][Z+N^G4EHHHKWCK"BBB@ HHHH **** " MBBB@ I&S@XZ__7I::^=K8.#C@]L^^,''KR*'>SMJ^BO;7UZ 8^LZG::-I6H: MMJ$BPV6F6DVHWLSD!8+2R1KJZN&R1Q;P123$'KL(Y/!_G1^-?Q7U3XT>/]4\ M8:B66R:2[@\,6;"0V^E>&K:^6&VLA#/).!>:Q(J:Q*X(C>&.0PPPC&/V%_;1 M\877A'X$^*%MIU@N_$MUI/A2W(WAI(=2F6XU>$E9%)2XT>TU"V;!XCE<-NW# M'X0@$*%+,P'DYSCYC;PM;VY; ',-NS0QXP-A.X,WS5^*^)N9XKV^&RVC4]G9 M*M7AS\L'0WJ7GLVX7]RVMTK['R^>XKGE3P]!MN,DZBDN5=D8E+ NH9&0@@QN M,I*>JQ,[@@J"&'/89/''KS5>ZO;6R3S)[@6Q4CAB2[Y(&$"E3@YPP.05R#QF MOR#&8[#9=A)X_%8_#9=3IJ3A7Q%:%*<)13:JTZ YOA[K6LSG^P$NM4_MFWUJXTNXG$GV8)8P7GZ>[/IND6=H))7:ST[3K'S_MES]JE0V4#S3R$&V?49;A M8%5&79+-'NW(KJ_&W7BLH[M!;2S1%-@,+=;\%:M8^-+6PT5]1M [:%;:IIS7Z:=,\$L+72Z64 M0W(BGC EC1A\5C_'O@JI3ROA'$X[$YCE?#.)6(P>,PN"JRJ9I5Q513QBQE.G MB4[46YJC[2515$ER\MT?N62?12\6\VH0S3&\.4LJPE>S53,\RP^!Q5*,G=U' MAJN'J5%*"?-R\S=U8_8K]CS]G:?X)^'[W6/%)LU\<^);?3UO[9)8)'T#2+2* M46FC_:"^9-\LHN+O8=CW*Q;"H1T'VZC$LF(R5(/[P,A0 XY60YR>.%//H.: M_#EOVT?CZK&1?$6D$[@1&WAS22F[(7<3Y D/R_+CS-N , $ CNO#_P"WK\7- M,FMAKNB^#=?BW$21+8WFDWEP"C*JI?)JWV*V;=M8R2V4B%59-@R"/U;(?I,> M$V H8?!J&#_ (OW M#Z.T:^%?%46$DT'5G_=S2"-Y'.DZH'6VUE51'=UMHXGBC5Y7!5#GZGBGD>0( M_EJ>0R -NR%)RK%L$G.:_HKA_B;).*69W@ZV78SEYE2Q$'!3714ZCBH M5'+[/(Y*6J3NK%RBBBO>/,"BF N1R .GK^G/^?K2$R ]%Q]"3WZ#<,_X9-3S MQYI1;LX]TTG;^5V?,_)*[Z7)YM$TI.]K)+77NKJWG=Z=22BH\O\ YC/_ ,72 M%G'.,]/X".IQUW'I]*3J02;OG'_ .3?Y,EHJJ;@ MJ>2F/3#!B>_&3C'OUYYX-/$V=IX"GAO7/.,<^I&>/7\#VE/FC'VE-RDKQ2FG M?RTZOHMV'O*/,X32O0I;KU/S<_P""C5W)!\/O >GHK&6(.TDK-)NRHYP5V\@_D*.2!ZD5^RO_ 4)TB2_^$&A:V8R6T/QKI9N M64 QPV>J:1JUO/*0 MA.2Q /S=^!7\[>*#G#/KU>;DG@*BM3O4JR3A9QIP5G.;U48IIR=DK7/B\UI5 M(8UQ]WFJRY*;\FFDM;%+4;L:=;O\TR]12JR)$T MD99"Z;H&68;T#*S*=F#M92!R",5SWAOPW-J5P]Q>6[QV%H\2^-:E.=.EB*[IQ:P MLYQM&.(JM\BHN3FYOEO<_P!#?H29;PC#@#/.))PH8KB&GF[P-2EB(4Z>.P\7 M5<'B<'"HYU)PI/WZ=>"C%.*DDB]X4T%[HIJ&H1(;4,?(@D!7SR%8*S*"NX(V M)5V[<% 3D9!]/5BBF-"51@ 4 &TA>0.0<8(!X(Z8/<%BQQHJ(B*J1*%C51A4 M &/E [D$@YSU. *?7Y1@,LPN4X6E2P>!Q&+QM7EA.4DW5YI6C>DI3;J3N[PB MG'FE975[G]7YECZ>,JOZUA\:\/0?/3Q5;-5"C0Y-?;5J*A[U*G;GG'6\4U9A M0,@'@.>3EPC%5'+<2*R$;0I/0 9&X^BY!8X4$9R-_ MPMX0\2>.M7B\/>%M&OM=U&240W,-K9SYLU969Y[Q 2MO!!&CSRR&X<"*-VVX MXKU<%0QF.Q=#!8/"SQ^.JUZ5&.5T%.IBZE6I-0A0J4J=.HZ;J2DH7E.R;NWH M>9B,3A,'AJF.Q6(6!P-&E.N\SQ*C2P<:=.+J2K0JUJM-5(PC%SLJ>J5DM;%7 MP[-J\'B70I?#HNI-:76-);3%M'=&DN9;^WBACM[=M\BV\KN(M0%HT#R:>]R@ MDCW;T_I"T,74MI8R7BF.YCMH%G50 IE-K'N/S;GVAVE ^;.5 /W6S\:_L]?L MCZ%\.+JS\8>+[Q?$GC"*&VDTY/(B&EZ"Z!LG3W,)DGGQOCD>27Y02RJ#M(^W M(HO+FB)EED8H0=[*5PHQ689YB,3@L1GL MHU8Y+4K/$QPT*KO",T^54:EY)56$/9N4)6C[1N\/\B60BBFFN) \\G[ M15X2X&R?ACAG/.),5FD)Y]3E7IT)^)LGX?PN5U(9)4A0K5,=6C&C1J8EM8>?LHP=3%TU=.K3HR MIS<4X*2;3/1_^(EO_@G3_P! 3]H\>Y^&'AG'_JQ:@N/^#EO_ ()X>3)]ET?] MHD7.T^3YOPQ\,+&9/X5.[XD1ABY^5(PZ-*Y6-65F!'9G_@W#_P""9>0#X2^+ MQS_U6#Q#CUZB+/Y5&W_!N'_P3/5T*>$/B\N&1@Z_&/Q,C## @AE56&>A*X., MC(SQY\:_@>IK]UQ]9>\Y3Q.#KT8I*4FZE.G3C.K37+[].$E.<;QBTY(]2=#Q MIY$I5>!;5;0_V?"XVEB(J=E>G4J5)0HU$F^2K4C*%.=I3BTFC['\/?\ !2CX M-_$7]A/X@?M^_##PQXU\0_#?P%X>\=:V?#FOV%MX=\3ZI)X"GN;75K1K6RN? M$::$?"_P8 MUWXFV6L'XA7GCO7M4O\ 1/'7@[PC+I]RR>$/".FZ1%Y/BM+E[)K6]N@\0*WF MQ71O8/VK_P!E#X3?L;_\$A?VNO@E\%M/U:P\ :'\'?BKKVGVGB#5#X@U-+W7 M@^JZ@DVK74$=W%&#NX:^M+FBE9:24='S]+7N?WFV_W/R_EG^M3.,HP]1CWYXR/>LY;AHDZ+ MG<@^Z[#!95_@R5 !.78"-!^\D9(U=EQM7\6:-H-J;[Q#JNEZ'IL4@CN=0U6Z M33K.W=E9XD>[NF2W4L51/-=X[:21UB@FDF98F_,U&I7A..%3KU.648*DG43G M:Z5XQ?:^B;M=VT/UB=>A12G6KT**=FE6JPIR>NR4Y+5[)7U;2W9PGQW^'C_$ MWX4^,O!T 1K[4].,NF^:4"G5+*XM]0TZ,NRE46:YLHK4R'!CCG<[E^\/YTKW M3]3T>^;1-4AEL=3T[[3IVHV,]N8;BWO=/N#%=VKK<3P+)&KH9([X2) D 9S% M,RA&_I&T#XM?#'QA--8^%OB)X%\1WZB5?L6@>+-'UB^!@B>64_8K*XDN0888 MI)I62.3R8XI)F!2-L)? V@:QK3)#^\U&Q@:>XLM^!)+" MLXFN+0W&/GN+6)WE4;\J!GX/C3@^&=8C"XNO*>"Q-"FX/VL*E*JY67(Z-.=) M.K/7W(*2YY)).[/-Q6 AFJ;HRC5@URSJT:E*:IQDM9R<:C<5!:MN]E\K_CO^ MS?\ LR^(?C7J=OK-]G2/A[8ZG";W6)H9I'U]H&\Z31=#MUB$=YODC2+4=0-S M';6]@]S.B.Z(C?5'QV_8C;^T+GQ-\&K*VMX;G[,MWX*$OV:WC>"'R6NM'N;J M=(9YY!F6>"5UQ&)%1S*JJ?T>LH]"TRW.FZ:MAI5GINRP_L^QD&GV.G(BQW4= MJUG:HEMI^;6>"[BS%'(\,T4+D0RAGTI/(NA#!&\;E5WQQR )(X5BOG);S18> M( X2Y1A&S':N[!8_-YMX(\)<1<+1X=XAP]7$5YUUB\+GU?#JECL-BFU.A["I M)R:]G)Q<:3E:6C:V3^KX#XPS?P_Q\\WX:QL*V*H6I8K*XUHU,'4HQ=JDZ]-2 M2YG&[;^AN:"%4"31B5U!P\Y,H1CP",G=C/ 2-D+\)N M&\U0EN+4A?LQTP.KQ*T)88>CA MIY-D=#'SI*<'C<1%864NG-&I&*JQO\5/FO)>Z[IV?YE_#/\ 8(U6XFAU#XI> M);""T5U=O#GA8O=W=PA1O]'U#5KR"."QQ(4,Z6]EVD=+J']%/"' MP]\)^ =-M-"\+:38Z'80Q*L=K90 S,R@LTLM_+YE_-))C]YY]Y,A&4"HI*UT M8U./R_.\U%$:LTA=IHX@PMWE>2&:>)C<6:X)%W;CR)(5F>%I'B\A[<5XTCK* M\MOL#KEH1YT91X%*H)49PSN[F=6TQ56,I8?$2W48M2C*]I-Q;7X1QAXC\5>(6)K5 M>).(*^.PL*SI4LEP%?\ LW+\.G+EO3PE*K&.)P\4_CM*,X*]E?6T@6-L1K(Q MX!9V)4XSTCSL4\Y)4!C@?,>E702'0;>""2W/<$CV] ?>J\K2(A="KD[?*0(Y M,C,RJJ$("R!B=K3%=D S-(#&C"J"ZM;E\)OK^A_PK35)^NDH>]%_X9)V?R/\Z[_@XE0O\ \%//B=$>"WP[^$: ABOS/X2T]>76 M*8J"SWP^^+M^FD^(_#GPYT#2M1TV:^T[X?W6EL;>XL)$^TKJ#0S2_)%^\D MCC'\T_\ P<1%1_P4^^*6_( ^&WPH! 59 ?\ BCK $,K/&"C#(?$D;!22CJX! M'ZS?L^?\&U_[*?Q<^ OP.^+&L?&WX^:/KGQ+^$7PX\>:M9:)#\-VTZSN_&W@ MK0/%-]IVG";P!)E'AG" M4,7*&896ZSQ=>.%@HJI'F:G.%1.RYFK;I;6/UN/_ 7._P""6>1_QECX>(W MMM^'?QB9MNX;SMB^'LKG"Y8D*0H!9BJ L/T;^#/QH^'OQ_\ AGX1^+GPH\36 MWC#X>>-[-K[PSXFM;'5](@U>&WO;FRN'@TS7K'3M4A1+BSN$Q2S?6[VVOM>U'7)'OVTN MPTG2Y)H[K59H(GM-,M$6VC@C9&D1Y)?R+B+!\&X>A&'"^/S#&R:G&I]?P#P2 MC%TJJO'FG-O5KKHKOI8_9>&L3QA/$U5Q+A,!0HR?[CZGC:>*ES-VC>-.C3Y4 MO-L^?_\ @JX-O_!-W]M!@2<_ /QWP>G&F8[ ']>O-?RB?\&P4B0?MY_&*61U MCC3]DKQF\COT5/\ A%OB7%Q]I&I6P^&:CJG*I@^&XI2:^UF]$FFTSX/C1N'B3X<57[J MI8?,IVEHW[-U)M1CKS/W=$M6[+J?LY_P6+_X+2:3^QJ-:_9M^!,%OKG[3FKZ M/#'K6MWH#>'?@OI^O6=E/IVKW0N'M+;Q%XXN;+4K/4?#W@TSVZ/I^I:1XEU6 M1M$>6SG_ )X_V>?^";__ 4S_P""M\=Q\??'OQ!N)/".HW;6VE_%7]HOQAXA M$.M7>E+<:=?K\/-$TK2]6UNWTI9//MKC3].\-^$?!^GSQ3Z7&UUK%KJ=KIGS M+I%J/VT?^"K]EI/Q:OKBZTKXZ_MK1:%XOBFOKJUD_P"$Y:WTP66BR>=H]N-./\ I1^"? ?A3P%X7\,>$_ >B:5X2\*^ M%])MM&\+>&O#^GVFAZ-X?T"TAMX[72=+TNPC@M=.M+:..""Y@LHH89;F*-I( ME5%B3U\[QV!\*^'\CH9)E.'J\1YM@88W$8O$T(8FEAZ-10(]$MQJUOH6 MCWGBGP+K]YJ5DR7$%IX?O+[23H]WJ$LB 6=UK%[IL4/QCUCX$_MJO\6OB!\,M(UR[\+^/? WCB_O?%OQ1^#U^OD7%OKOA M34_%&H-J6N6NEZ?):+>> EGOM+\0Z1KVE>+O".K6$5E+H-W_ 'TW%K!=(ZR! MI5,;12 ,R1R+*/*E$B#$DQZ[X;6_985NI+KPKM M);Y#\+P5ETN+>$<=G$*F755BL5E^+SJM+ 8B&'E[ M6=&7M9256C4494ZBC&TH.RMNO3?^"QO_ 3,L_VU?!7A?_@H)^Q;/I^OZMJ_ MPOM/%GBWPEH;WMO&-2%UJ$]M?I^E_\ MP;F?$SQ5\1O^"<%OIGB:XO+N'X3_ !A^)'PY\-F\NYFDE\/S:?X8\?6EHUXL MC!;>TU+QUJ%E:,8Q;Z586T%K!#'%:OO_ !Q_X+^_\$[/@S^RYX@\)?M:_ +Q M)IWPSUOXP?%%[?Q+\*K>\DT>=/'5Y WB2V^(WPTTS38[34M-LUN].CN/$]I; M2II?AO5WTN\T>RTRXUW48+%Y/5P&95(L'"MC<)C:U#AW,XI+$49QG*. M&EC9QBWAHQ?+.?MG.,(QG2J2^"2G,*>-P-'*?$C(L=4P.!QN#I5.(,LQ$W3A M5E*$9XBG@:,W)XJ4_P!Y"DJ7LY5)ZO9X(/!]I,+G39/B1XR@M[.>=-%T?5DC/ARPCDL MIO&>IVFH:98W=@-'NKV3^;3_ ((^_P#!,OXI_P#!0#XVVG[7'[2<>I:K^S_I MGCC6_%&L:IXNGM]7N?CQ\0+?4FOYO#,5C/)=6W_"!Z+K4,4?B6]DTJ#1?%.D M?:?!T=F)+F\OU^2?V&?@MXL_X*W?ML:-X5_:F_:1UQ+E? 8U&_USQ+K[2?$C MXB>%O!3:)8P?#CP''.=-L/[=N=.O;T:O/<-)%I]GI&LZ]IUC%J$NK-JO^BK\ M*OA7X'^#O@?PG\._AAX37-V8V7DSR6&\*O1E&?L\3A5:I2I3<;5*DI\MG+W;)GQ?_ ,%'?^">WP\_;V_9PO\ MX3:HUAX3\;^$;B/5_@]\05T6+5=1\#:Y:RZ?->:;;6_VS3;Z_P##'BR#2[73 MO$V@IJ]D;\1:;J%K?6.L:%H>HZ?_ !7?LE_M/_M-_P#!%?\ ;<\3_#?XMVOB M&_\ ".EZY'X<^._PYDUN\FT'Q7H.K%3X>^)'A;^TDGL8M3M;.YBUS0O$]G); M1ZWH5E)HNHP+=MJUO8_Z,LD7F03+)(LFX@L"4V(NX;RWF*0%"[MW!8+NVG=M M-?B5_P %C?\ @G'\"OVN_@-XP^+VNZAH'P]^.7P6^'VM>(?"/QFUO4$TS19- M*\.-<7P\#_$2*XN8-.N_!_B6Y>XETK4+K=()+J&QAT25K&_TV>#4%U.2SDM+LZ=_"G\1_$_[5/_ 79_;U:T\$> M&M1T322L=GX?\.ZQ?3:GX<_9_P#A98:C91:SJ'B34;80-_:<&(+'0))=%BD_-W0?BQ\5_&W@;P'^S1J/QA\36OP8A^(MAXAT;P]XJ M\4:QI/@#PCXDUPV]G'XQU"XGDU*30DTVPU6>]UE99KQ?#B6FH>,M.M)]8UO5 MAJW^B[_P2\_X)^?!7]A;X"Z/X;^'&JZ-\0/%7C_3[#7/B3\:-*M=.CM_B#?_ M &)9;6T\.S6QNEC^'UG'>W,GA*RBO=2DNK":;4M1U1M0\Q)OK\RRS!>$>"Q> M(CAHYGFN?*N\KJ2I/$8+"X#$7M'%8E_NL)C.64/:8>4'5NO9IJFI'R679IB_ M%7'8;"K$_4,LR2%.&9157ZMC:^,IV4JF&PKO4Q>';@[8B$XT[-2M=Z?27[&W M[+7P_P#V/_@5X!^!?P[M9CI/@[2/*U'5[]$76/%?BJ4(GBCQOK$SJ]U+?^)M M0C%RR?:3:I;?9D@A\N"%Z^KL-_>_\=%*EN$(VEN.FYBQ.!M4ECEL*N0J[@@R M3M#'-6:_#,75>.KSQ=6256O)SJ1BXN*E)N3LTHJWO:6BDDDDDDC]RP%&.7X6 ME@Z?/4IX>*A"<[\\HK2\KN3OIW?J?YUO_!Q4N/\ @IQ\3L@-O^&_PH217**" MO_"'6"L%,D,Z*Y'"L\,BJY!( &X?VA?L7_'SX(:1^R)^R=H^I?&'X6:9J-A^ MS3\#K+4;&Y\>>$;:6PO--^%WA.RO+*\@FU.WGANX+I&1XWAC*D%6C4A0/R>_ MX*7?\$*_BE^WA^UAXK_:+\,_'KP+X#T7Q%X;\(^'[?0-9\(:[JVHP-X9T1-' MNYY+JRU:TA833VZM&%C!".0RYKX%'_!K%\;155(; M6! LD_B"22()%9Q(BQ21I\SJ5*L%'[?F6+X'XPX/X%R/-\_EE6(X8PF.CB:L M<-5J1C5K1;H-3A*TXQE;VDX\J@FVU+E5_P .RZAQCPQQ;QQF. R'Z]A\]Q6# MJX%*7[R-2/(G2E*+:BI3ES-Z.-[G]?(_:*^ (_P":Y?"+_@/Q%\'* M?^^AK1(]\#B"HD4N1G6 <[=V#N'/)! MY!_D+_XA8?C9W_:U^%3#T_X0#Q)S_P"7"/KUH;_@UA^-I!"?M7?"J1B-NT?# MWQ%(Q#<,41_$#IO"DLC,C!'"OCY:^47!OAK!\\?$.%5QO)4XX>O*51I2:IQC M)I-S=HI-I>]J]#Z=<6^(TFE_J)4HWT]K.K!0IWNO:2;;M&%^9NSLELS^B+_@ MIMX\\)^.O^"9W[:>K>#?$_ASQ7I<'P+\?Z?+J7AS6;#6[%;Z'28;B2Q-UIMQ MYQG"+EF.%4$G!_>K]FG_@D[X^^ __ 38_:6_82U?XQ>#]';'QQX4\%^&],_M#2[N\NKVX&GW?A[6KVYCM;J"*ZS;1 MP/:@RR-YM_P2=_X(Q_$3_@G1^T+XR^-'C'XS^#OB)I'B[X,:[\+DT71?#>L^ M']1LK_6/'G@OQ?:ZMCJ)'!F6 M39]G?%/ .=9A@O81RE8BGF7)44E3J8J;4.7W5[6G:2]I-&/%7QSN_V@?V?O%]L+L:9K%[>^-(OB OAR MW;3;6[FTW5?"^MW-]X8M=,^SW6HWUGH-OK5G!)_ L^ MJ$+'XBTFXOGTR[:'2_$-GIE\' ^K/VHOV5?@-^V+\+=5^#G[0G@VW\:>#KO_ M $JW+7'M6TQK34M"U2RR[)-;O\ 8;F-3;75A=VTKVK_ M ,P'QQ_X->]^ K; M48]9NK:.,1RF/X?:+?1);37=S>3JX"]-3/N&N.N'LKR[B?,:F49OE%*&'P.8 M4<-/$T52BHLU*48R32U5U<_K0^)?Q6\ _"+P9XB\>_$_Q=X< M\#>"/#5E)>:WXCU[5(;#2-/MF>.V@:\OW4Q6\MW=SV]E90,'N[Z_N;:PT^UO M=0N;6TG_ ($O^"U'_!1W0_\ @HY\;?AKX&_9_P!+\3ZG\*_A0_B+2?"ES>Z+ M>6>L?$/QOXWN- TZXU"V\,%I=:TY;:+1HK7PE8ZII6GZMJ]EJ>JWPC,5U:6] MG]A6O_!MW^W;X\U'2[/XV_M:?".;0;:X\F&^'B;XN_$ZZL8B94>'2] \:>&? M!5O;SK9Q^?#!'J"(%8/#<@0K,_[??L"?\$0OV6?V&_$NF_$^[N=4^./QKT29 M'T7XA>.M-T_3=)\%W$,$L"? L9EL]#U!'N5C;Q=J6I^,O$RV4TEO;:S9 MVK%5O)*O!7A_4JY[@>)/[?XE5&I3RR2P=2E2PU=PDJ%52JSY54A4:FE;FMS< ML92;(SRGQCX@U*&25\DIY!PYRQ_M!T\9"KB*KDE&I"-*-*,IP<.91Y9)-M?+ MD?V/V^'7_!&#_@EEX'U3]I_4XO#FN70\0>/_ !3X5LHX[CQ+XE^*GQ%W:OH7 MPC\,:([^=K'C:#0K#1?#%[ 9Y=,TO5-$\07^H:@OAN""]/\ +9X2\,_M5_\ M!>/]NW4)=8U75-&\,R+/K.HWDNI7&M^$_@'\#CJ,T6GVGA*:XO=/_M;4+B=K MC0=!N9CHNJ>,?%%Q=:U?.FC7NM7&A_T;?\%*?^"1/[7G_!0SXS6WBG5/VI/A MOX*^%'@N.YT?X3?"@^$_%&HVWA:SNQ:"Y\3ZI=VNMR'5?&6N) TM[=PP6&GW M&A6J>'Y[.+1E:V3]0_V#/V!_@9^P+\(-.^'7PJT:VG\2:K:66I?$OXDWL<4F MN_%+QI#96FG2Z]J5YG,%AIDTEUIGAG04EMHM TR[NH[19M3U36]7U7EPW$V1 M\-Y-G/$,:LES\\80CSN<4N:,4[] MF+X=S?.\URGA_%8?ZKP;P[0H5*-6%1+$8O%8/D=.-?"\JE[&3BU.7-JOB#2T<7NEW[SS&5K!7CB_77XF_#/X??%SP1K_PU^)OA_1/ M&/@OQ-IEU8ZYX:\1117EEJ.CW#SF0EI)$F%U%;6YN;74(95N['48K;54N([V MSMKFU_EN\._\&[GQV^ 7[147QM_9._;"\,_#JT\*^,]1\1?#*+Q%X0\1ZCKF MF:+,\JZ?X.\5:AH6IV5G>Z=-H]]?Z-X@N]/T6SLKK2)3?7NGR:A =1$KB7*. M-.&'A>*,8\%GN!A)Y?F%.G]84XJ,U'VM2DTU*%J;G&NIP]Z$DZJ<-9MP5 MG]#&\*T*6,R;,90CCL%5Q4*$O:3J14HPI3IS34DY6G>RO9JVI_6-J=Y:6VFW MUXMU9K;QPS7+3W%[!;VT4-IM>XO9KMS)';VEDY_TV5XI3;(CRF&=D6UG_@X_ MX+!_\%//&/[?'QATG]D/]E.[U[7/@;IGB;2O!]EIGAZ.*YG_ &B/BO>ZG%9: M;K M'$\MQX5TW6I]*TOPKX8NX+[2[F[BGUGQ%<+%-:Z!#_4%_P % _V5_P!K MW]LG]GS0_@)\/_CE\-_@C;^,-,6V^/NK:1I'C'6[KQM:WNGV$)\+^%)=/DM+ MGPUX&UG4XM2N]?O;UKZZU&)(+":9;"75H;[Y9_X)A?\ !"_X9_L.>,+CXX_% MSQ1I'QT^.^FW-W#X!UZWT*;0_"GPZTV738+2>_T33;^\N-1U'QA,8M0LX/$6 MI7I.BZ%/I^GZ+8V%W:7>HWGE\#XSAGA>&-XPSFM@\UXHP3J8/(L!%JIA%#]Y M"CC:M96HPKJ?)-4W&4XM-I\SBEW\7X/B'BAX/A/*:=7*>&<7*E6SO'RO2Q?M M'4A.K@Z=)\TYX9IR4ZJFJ"?V%H/'OAGQ+-XR_;%\ M/6L?C[XB?#O3[C9X9USPO-X;TV&_^&'A@")K:]\6^$#IESJFGZU<2"/QEJ3: M[I5F=&@_L:ZTVA_P0T_X+!6?[.5_:_L=_M.ZGJ]K\.O$'BQK3X4^,M:O+G[' M\)?$>MWMII]]X'\6B^D=-"\"W?B2Y#Z,+8"7P;?ZS=_\)$-1.II;^%?[>'M8 M3,T,*-B>5%)=)*F:Z^*V@:MX6DUC0_$/B]'M7LO&6@:9HTN MG66A^*=7CCNM1\3&6*33M>U*VLM1:QM;_5=?U'4_7R3CG"<29-G'#W&56"IX MO'5';C[U&@Y22YU>,(*2E%Q=CSLXX(Q7#N=Y1G_ =& M,JF#P-/ 9AA*E94*>(HQC&-7$:QE&M7Y$WR64I2:2DGJ?TJV5Y<7>QFC55*2 MLV-Z,I1XQ"=DF2YN8I#,ZJ3]C=#:R//)^\K6KX#_ & O@U^TK^SY\&=#^$G[ M1OQ;\(?'2^\#VJ:+X*^(^B6'B73?$E[X8L46SL=-\;PZM<:S87FKZ3;I'8PZ ME9ZX9[RWC$NIQ7E^6O#]Y>>_HOY'_&ORG,\+0PF,K4L-B*=>BI-0J4Y/DDDV ME**E[R35M'L[VNK-_J^65<3BL'1JXFDJ->45[2%TTI65]4DGUV7;S'*JA0?F MR%QEL98G!)(4*H)(); ST':D<*!\SPIR2E&$8R:;C=-Q4DO=YHWM)7W3WV.RJYTZ<7*;ES64VDHR<7H^62U MB[7L^CU(,+ZK_P!\#_"G#&>&&>G"@'GC.<=NM24R3[A^J_\ H0I1HUE*+*?M&+<' MX(_%,6C74'?"GA*3Q!I?PVCTCP]X2O=0-OJ.M:+XO:^UCQ3K%C% MX8\(26EYJ*ZAI:WEOIT.HYM+3$LZ1[[E_MW5.;%P>0T95@>A5CM93ZAE)# \ M$$@\&LNVDD,TZ%W*'Q"T94LQ4QC3U<(5)P4#JK!2-H90V,@&O*Q.683$5ZM5 MPG"I"$I*4:DDN>*;4K7[K;;Y&7LJ]:O.G+$R]G%74>5?GO>W7YGR3K/B#QOX M/^+/C[Q)K\5G?W.G? S3DT&#PZFKQ:7>ZQJ'C[58=+MQ!JH:;;R M3+-#&(Y#N15^9>)N]&\3^#/A%\9/A_XEMM5CU?4? U]XSMM;U2ZTW5#JOB": MQL=.\3W DTR\U2Z46NLVL?BRW@N$$=C8>(F,]M<2V$LP^\BS>7;3Y/G-$T;3 M9/FL@U"W 1I/OE &8!2< ,W')RV6*)KJ.!HXV@NR5NH613%$7&2E&$I*ZDGS*ZDM]A5(JBI):SM+EG)) MN+:TE9WNT[/Y'PWK&A7XT#XX:#+X8B^&;ZC;?""T7PEX/N7GLK*RN=7,=YXV MTO5]$T72EN[^[DOYM$U&U>&=(AX-2\N8I;*G>);2#P%KEUJWC2[4V-E:Z78:M<6ND6>A65U,+^W!U M"'4)M0DN+40_75P2ES;!"4#7%^&"DJ"(X\Q@@8R(R[E >$+L5P6.;+,WFRMN M;(&\8WXTC5[/Q!)JB:(]MJE]X\U,(T6L M)RFY]&:7,M[ZJ5 MNMNG0_/3X26^CZU\!?$WA;P?9^!8?B)=_!%+5T\)^&]:T#Q1?:[_ ,(]<)!) MKLDMAHHU:\6^EMY62T*SSRLZQ2('B=/>;'Q#X=^+7CGPG:^'X[G7_#OA[P[X MMM_%D-]I>J6VD6ZZGI^BZ78:-J\&L6MM:WFJ)>QZ@LVGK%>SP0G[4+B/8QKZ M,ME5[&ZD=0[PPQB)V 9X@NG6-PHC8Y*!9U69=I&)E608*#>Q?&FPS MC<2V)VD16F&6DKV? MDV']%T_3K7P'JNEZ?<76C MW%_XEG\3W.JVFEK#(R:I=B_>31EF@3ZVO8XXS&L:)&LUY;F8(JJ)3-=VL#PF%JT\11=.24,)O$FJ_$%/&VD>'?$4GA;X0ZWIOAF355NK32H;^+5K M9K?XAW7@N[)OAC\*D_M32C!'J%M;6_\ ;EQ>>3;F M4M;WDMQ/++Y:GR_I)8H@;:$1QB&2UNC)%L7RY#+<6C2ETQM?S6DD:3<#O,CE MLEFS#D^=;\GY]4G#\GYPDH"!O[P01QA0M"&)JQY^:%TV MFKIJZM):JRZ^?I5&U-)22J7M?F[:=[]++Y'QS\,-7T72/BM:>&K:RT/Q;XBO M]0\4SZEXL.C>(]"^(NA6CVFIZE'/XY&K0ZA:ZYIMX\,>CZ9JUCKEM9-<7=F( MM,20LQ^UOG_V?UK#L)9'GO5:1V":]?Q(&=B%B5&98U!)"QJWS!!A0>0,UTU; A8?!.C[2#KU*OO?%.[>W=MD+$RJ2J XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jun. 28, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 28, 2022
Entity File Number 001-31326
Entity Registrant Name Eloxx Pharmaceuticals, Inc.
Entity Central Index Key 0001035354
Entity Tax Identification Number 84-1368850
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 480 Arsenal Way, Suite 130
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code 781
Local Phone Number 577-5300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol ELOX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2219962d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001035354 2022-06-28 2022-06-28 iso4217:USD shares iso4217:USD shares 0001035354 false 8-K 2022-06-28 Eloxx Pharmaceuticals, Inc. DE 001-31326 84-1368850 480 Arsenal Way, Suite 130 Watertown MA 02451 781 577-5300 false false false false Common Stock, $0.01 par value per share ELOX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://eloxxpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2219962d1_8k.htm elox-20220628.xsd elox-20220628_lab.xml elox-20220628_pre.xml tm2219962d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2219962d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2219962d1_8k.htm" ] }, "labelLink": { "local": [ "elox-20220628_lab.xml" ] }, "presentationLink": { "local": [ "elox-20220628_pre.xml" ] }, "schema": { "local": [ "elox-20220628.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "elox", "nsuri": "http://eloxxpharma.com/20220628", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2219962d1_8k.htm", "contextRef": "From2022-06-28to2022-06-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://eloxxpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2219962d1_8k.htm", "contextRef": "From2022-06-28to2022-06-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eloxxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-077083-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-077083-xbrl.zip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ⅅY]>*I-."\,RV'!60A8=C*S+*><3SM&GI[$9J5S-6 MG(IT#DI3Z? )IGL,K&9"!(/3'C<4*CEUB.]\@M*;&Z8E_&GQZ*Q4NA03IJ@4 M*?^#2A%<-XU%G8MOT?EG+Z+30^H53Z)S2^-I0V;+* S<'^H*7G2%Z ^8"XX$ MJ/'?C]1B9*G(1E'U0K+^,G<@8FYG!<[D*?<@'O PC[H%\>Q:ON^](@=,R4J! M5T.O^(3["?BNEG]B8'-#OABC=J140"/-360G:NY^P%N,15/U+?U]5*+5OY'9 MK#_\>J5; 7@<<&Y Y!R(1_UB-ES'F5ZVIA9),\@<9\2];5=[@@< M?;6Z4]0+UVQ>X*Q !L'E5[" ?4I4260[:PC*'K?@7$+[NTY1>P$OP&5J+[7VKP/IMLT58; M-:S-C2\_B%;\?1!M'0?1GO,J4L\R]&=C"K\NN$8\VV8"-_F2+W;(S[#^B#CE M5>IN^^BT<7'9P:\I>V.DO4358A9O5A;GHE^;D.IE9;_.;!):F#S/O=_-CHG MC6;K\J+=;!QW(78Y;?=G,2?GY$C7&W&7- 8#*NZI$75IB]?E%2,P^4W6 MSV+LZFB(L^QA77I-?LE[OJ_-,$RMY+L?MZ#+&2WD;_Z:F)TO9J/QW2M^&>P,QPUG,KHY MW>GL]IA]]M'D7W3WS^[=S1]WEW]^]_[Z7CT9YT\/S%WVQQ\56G:_-,UV\6;4 MN[EJ?];LV]MF92??OC/MH^T?;7':VA%'=M?^=I*[=&ZI^?+OV[.M.$=/[J\O"_O>CNWAQ6GT+@<_773O!M\[IR4OKJG._3G MS=#^5G!ORL<'WB!W7_ZC>.I^:C4^?% L^3]02P,$% @ E4/E5"&QFP#* M"P #DY+3$N:'1MW5IK;]LX%OUNP/^! MFP6*%)"=.'TLDGB"<5YMNGEM['0>7Q:41-ML)%)#4G:\OW[/)26_FG8RLTFW MF*: $DDD+^\]]]QS:7??#R[.#YJ-[ON3WC&NC/YU!V>#\Y.#[E:XXNE6];A[ M>'7\"^L/?CD_^6%CJ)7;8YWMPK&!S(5EEV+*;G3.511N1*POC!QN8""&7M?C M$IUIL\?^OM/!S_8^>^P\^RSG9B35'J-7,=")>]?BF1SAEI&CL:MN294*FG*[ M_4:JC8,7*K;%?G?K>LV.QZ^[;O&?LZ-[>'!R/Y:Q=,W&[FZ[T]TZ//A?K%JS M8MW(;^:=8$?+Z<+;,K_A%]UC,?Z-T<_;+A\ M9Z>SN_MV)^W\6]SO[K8Z,A]M;W?:GXK1!NN=#W[8V/@+N?)!8"5829B HDS? MW[/K,38F;3;TD!U+(Q*GC7UBV#UH MX]G<%V??8*USQ,'R&3R0&FWO9,0^'$?LXK#'8B/5R#*+$7((-RFDGK@O,+F MI]C(Z"E>8+'43B1CQ#TON)+DNK'1Y6C,QL(PHS/]B2I-U&S0O1O^2=@QN^9&W(WANM2_^8';6!JL+L9XWSI1L%1/%1L:GZ+M85)&;NY[+4< M[!!.I&PDE, D%#_#"TJ?H4;:(/(LE59P2\8[G2)%>452J0\V+PHME&/M;J??!C64J'3O2 M>2Z=$\(/PE^%4)8[J=7B49L=E<:007&@SC"M97\L!]AC4V#,P264!P5\LIH* MWH V.]59YFFJV^]LX;$5W./M9\0>T]< M\3R87V0I;8@ 6Q.[I/A.@#4#M]=DO:#BJ73CW^7X!;>G)54%3^V9QB].(&+5 M+.3W(1":2O^ Y^2_.<\G?LJ .?(R<'<-PI>D @*F3JZ6!C0;:Y4A>F'\WICE M,F7]$I!CO=&(FRG/HH>G>C!7VZQRTGOL(:GP.M1):1FP++A!XEO'1Z)V5K.Q MV+X$,O0D>(!GV#-/L">+_6<9BP7\ZHS(!::8\*SD<28H^X(=V/ 4 $1TI2K] M_;B463HG"3N6!2NTE3ZIP!BKU#!K5P[XGB%8N?:,(?@%MQ8[X0Z4$>O2+:$H MDW=UM7)CB %B.Q\"07I+,9ZFB*H4N MRLQS$:+KUQ;WB21VA9,_@247E+" !>$$CRD>8*72^8C0>\',6PJ&;D[YH\ZLAYYWL(1G#E5)= J \7O -FH+"P'!DB MDK;89AYJZI0*&S>$82"OAWJ4 MD1;I!*;5I0'S_%;*BBP ZE_E'7+K&W+$$YU$H&R=7ET.UF9%U4$])R6X<;"< M0G-1TVQ(&XJ-,%]@_R]T&*3*;+@5\,.T&<%U_PF.]WR4\SML8+D62#4!V$EL MA0H&^)E"I83,7* MC_,6,GBT0,Y)PGF5I8B-:F42VAV"2W^&U%P;2C90PZMM5JP49Y::$FH#R\B4 MG!NQ*8@6J8#EIB14,ZLIG9TI*104PN"/R@N8O?/VH;I-AA=()YE(%(V05,AW MJ-FSZZOPV(+=#69$JDV(#H92<950"]Q& T 8/1AH1F9%+&A),1SZ]/4R- O5 MQLM%2',$G30IM@.$>+DSX3*K!4%5N.P>NS(C/9G=LTV, -*P+G8/9D7S<#$; M0CZ3C9O SF0&D>YW#ALQC? AVV(H7%!D9&YLM$PM!KX3.7S'V::F'25>YL49 M:)VF;39NA!O/10Z$M@'$S*^'1&:8ZD MRTJ_[R$QX P)6I\M]* 6X#],<-ON8U('M:Y ]14^E)AFLU9 ">)R-$-;DABP M$G*.CA2KQN>$HYLPBAUC+KC%-U8?);&5Y,M8S#R"B!&H=%#-"0C#1KRNIAL8 M.D;9:>'F4"+LR6)-+X'].&R.1ACI9@@\U$.[V6BO9NI89Y ^;JK981^^&0$0 M=M'G7$!D\60,NG% XAD @EH,%&'U 7) (2ZC&;&F7Y2ZP94I!ICB5@$@QI() M&'4T1B*.=.0)EB.]1Y)\@@U? YWP[[D/1F@=V=%IC^HEZI0A.W%_TY.8;Q"H MFN&B>"Z6.M3%SOXILFSVLF,]\*+]T'/RW5HN=2I&E>PC_2.QC/'@ V8ME6*M5?>C1/3[[6-NP?*#= MV5DZT:X/L-_2O5@;H&1^[S#CR1WK8'&K,YG"@.O5^;QERQOO;F'-!Y8'7_*[ M5BP06MA8>)N737K[@$5DYA]=/ I[T-/__I)1C2IV-AS_60 >GDG9M5F"EWZG:$G(%O0\0G=:UTX9Z3=18 MG6$*:+BTZKBA0+UP\NT2\:U42D- D>@8W-X<7K5^O>CV;Z\/!A?=+;JB7HB< MZNN,N3E?,P@,1_6"%J6/"KRT\AUEU75#!N/*;FH++BH+L&IOY&7YYLU%S[X, MZMS1&4.,OMS7M)/R#K]I.DN9C^^+3 1I]"Z;)9K:!TQQT$3LY_[FUO1.%4SG?+L*7L*2$0E@5OU6;&&0E==HD MFZL9*R6-SC=K4:N*EG (:1.6;3;PED,+;K^ZC^6H>QE NNE4Z[1JP6%++\VA M?!"JT!IMGA[W7D+M6NKY%:GH4^@E-C!$WL':\"+5U;#19J.NL8XZEKK$'IW. M)7!H:!7*J&\7\M+-#W*6CR+"='YQKQ!B(=3LV-E;5_#'[$X M=>DT$!L.75I8(*>S![D5=5V-.2J,+P:MC<7\$]B@\5?Z2E$$L01\7&J* M?C(^"GVE;_#PQLP2GKWLA_1EF[=]1(+4\N718/MUY]6;U[MOX+?;K;/SE0<[ M;U__XQ4@7IV"D3/)JX41\T6Q.[@VMQ2]>2=K?<*L?S*QD.120?/Y0[?%T]#+ MX%(??7SNZHC=R924^D-S\M*%STR:C53GU)#181_R-6Q^=6043EB14;AZ,V%\ MQLW\'!7O>=E!I_C?OT1;*Y4Q4$(=MTI;=0*/X>V-@U. W+?44LV/CR+P*;F$ M34CU5K;<'DRGT[:@L(>NNXW^N+MU>_!TYY)?,?,Y2OL1QJ*__49E_$]/>.;+ M@O_VP)/-^4&/%?M)ZPPQ3Y]3?,)2[6FUU(]3;&4JDSM1H^<)-_7Z]:OV M3N=5>_O-]MOO.: 7=&[RA/.=\])0/3NB3TS2V?.&,PN+_5B?/":C+T?RN>CP M*VWESCZ[*GQEV&/G)"^^FR[S*5N^Q_;?6_2=P? E0OJNX7\!4$L! A0#% M @ E4/E5(%>R"X\ P _@L !$ ( ! &5L;W@M,C R M,C V,C@N>'-D4$L! A0#% @ E4/E5&V'L-W_"@ ;(< !4 M ( !:P, &5L;W@M,C R,C V,CA?;&%B+GAM;%!+ 0(4 Q0 ( )5# MY50\9#X.5P< ,=8 5 " 9T. !E;&]X+3(P,C(P-C(X M7W!R92YX;6Q02P$"% ,4 " "50^54*!\?Z/X7 #?A0 $@ M @ $G%@ =&TR,C$Y.38R9#%?.&LN:'1M4$L! A0#% @ E4/E5"&Q MFP#*"P